Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Calysseo is a private joint venture formed by Adisseo and Calysta to commercialize FeedKind, a methane-based single-cell microbial protein for aquaculture feed in Asian markets. The company operates the first industrial-scale FeedKind production facility in Changshou, Chongqing, China, with initial nameplate capacity of about 20,000 tonnes per year. Its core product is a non-animal, non-plant alternative protein ingredient produced by fermentation of methanotrophic microorganisms and positioned as a sustainable feed input for fish and shrimp. Calysseo functions as the exclusive licensee of Calysta's patented FeedKind technology for its target markets and is also evaluating a larger future project in Saudi Arabia. The business sits at the intersection of industrial biotech, cellular agriculture, and animal nutrition rather than human therapeutics.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Calysseo.